Palvella Therapeutics (PVLA) Interest Expenses (2014 - 2024)
Palvella Therapeutics (PVLA) reported Interest Expenses of $181000.0 for Q4 2024, down 17.73% on a QoQ basis from $220000.0 in Q3 2024.
Palvella Therapeutics (PVLA) has 3 years of Interest Expenses data on file, last reported at $181000.0 in Q4 2024.
- Quarterly Interest Expenses changed N/A year-over-year to $181000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $181000.0 (down 27.31% YoY) and the FY2024 annual result came in at $430000.0, changed N/A from the prior year.
- Interest Expenses retreated to $181000.0 in Q4 2024 per PVLA's latest filing, from $220000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $220000.0 in Q3 2024 and bottomed at $29000.0 in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 181,000.00 |
| Dec 31, 2024 | 181,000.00 |
| Sep 30, 2024 | 220,000.00 |
| Sep 30, 2024 | 220,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Jun 30, 2015 | 53.00 |
| Jun 30, 2015 | 53.00 |
| Mar 31, 2015 | 4,170.00 |
| Mar 31, 2015 | 4,170.00 |
| Jun 30, 2014 | 113,793.00 |
| Jun 30, 2014 | 113,793.00 |
| Mar 31, 2014 | 109,289.00 |
| Mar 31, 2014 | 109,289.00 |